CN108813614A - Antidepressant application of a kind of agalloch eaglewood effective part extract antianxiety and preparation method thereof - Google Patents
Antidepressant application of a kind of agalloch eaglewood effective part extract antianxiety and preparation method thereof Download PDFInfo
- Publication number
- CN108813614A CN108813614A CN201810608872.4A CN201810608872A CN108813614A CN 108813614 A CN108813614 A CN 108813614A CN 201810608872 A CN201810608872 A CN 201810608872A CN 108813614 A CN108813614 A CN 108813614A
- Authority
- CN
- China
- Prior art keywords
- agalloch eaglewood
- effective part
- added
- part extract
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000271309 Aquilaria crassna Species 0.000 title claims abstract description 70
- 239000000284 extract Substances 0.000 title claims abstract description 58
- 239000002249 anxiolytic agent Substances 0.000 title claims abstract description 37
- 230000000049 anti-anxiety effect Effects 0.000 title claims abstract description 34
- 230000001430 anti-depressive effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000000935 antidepressant agent Substances 0.000 title claims abstract description 20
- 229940005513 antidepressants Drugs 0.000 title claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 35
- 239000000706 filtrate Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 238000001914 filtration Methods 0.000 claims abstract description 17
- 239000003960 organic solvent Substances 0.000 claims abstract description 17
- 238000005238 degreasing Methods 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 9
- 230000006837 decompression Effects 0.000 claims abstract description 8
- 239000012530 fluid Substances 0.000 claims abstract description 8
- 235000013402 health food Nutrition 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 235000019441 ethanol Nutrition 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- 229920005989 resin Polymers 0.000 claims description 21
- 239000011347 resin Substances 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000011010 flushing procedure Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 4
- 239000002250 absorbent Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 241001122767 Theaceae Species 0.000 claims 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 239000002893 slag Substances 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 4
- 208000019901 Anxiety disease Diseases 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000036506 anxiety Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- -1 TCA) Substances 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- 241001533085 Aquilaria sinensis Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940035613 prozac Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001229135 Nassa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001534930 Thymelaeaceae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000001353 anxiety effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 208000011736 mal de Debarquement Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention proposes antidepressant applications of a kind of agalloch eaglewood effective part extract antianxiety and preparation method thereof.Agalloch eaglewood effective part extract is applied to the drug or health food that preparation has antianxiety or antidepressant effect.Preparation method includes：It takes agalloch eaglewood to be added in water or alcohol to impregnate；It decocts, filtering；It collects the filtered dregs of a decoction and water or alcohol extracting, filtering, merging filtrate is added；Filtrate decompression is concentrated；Medical fluid after concentration is added into water, heating stirring makes to dissolve, and stands, filters to get filtrate；By gained filtrate after organic solvent degreasing is handled, extracted with organic solvent；The concentrated drying of gained extracting solution is to get active component；Or adsorb, elute, be concentrated and dried into mistake, obtain effective part extract.The agalloch eaglewood effective part extract that the present invention obtains has significant antianxiety and antidepressant effect, can be used for preparing antianxiety and antidepressant active drug or health care product.
Description
Technical field
The present invention relates to the technical field of medicinal plant extract, in particular to a kind of anti-coke of agalloch eaglewood effective part extract
Consider antidepressant application and preparation method thereof.
Background technique
Also changed with living-pattern preservation, the spectrum of disease of population of China with the improvement of people ' s living standards,
The neuropsychiatric diseases such as anxiety, depression have become the killer for endangering human health.Neuropsychiatric disease such as insomnia, anxiety,
Depression is interrelated or coexists, such as insomnia can cause anxiety and depression, and the patient of anxiety and depression is mostly in turn
There is the phenomenon that insomnia.Anxiety is a kind of chronic, disability disease, causes huge burden to personal, family and society.According to
Follow-up studies in 3 years to 30 5.14 hundred million population of European countries, discovery anxiety disorder whole year disease incidence are 14%, occupy neuropsychiatric
First of disease.American Psychiatric Association (American Psychiatric Association, APA) presses down depression or severe
Strongly fragrant disease (major depressive disorder, MDD) is defined as influencing mental state, thinking and the behavior of patient, causes patient long
A kind of chronic disease that phase feels sorrowful and loses interest to favorite things before.In world wide, depression is to disable and cause
The principal disease of labor capacity is lost.In the U.S., the disease incidence of depression between 5%-10%, in addition in primary care and
The crowd given someone extra help, disease incidence may be up to 40%.The year two thousand thirty is expected, because financial burden will be existing caused by depression
3 times.Meanwhile depressive patient is total to probability, cost of other diseases etc. and significantly increases.Depression be also cause suicide it is main because
Element, nearest 15 years, because Mortality of suicide increases 25% caused by depression.In face of huge anxiety, depressed crowd, although close
Year certain progress achieved to the screening of anxiety, depression, diagnosis and nursing control aspect, but only about half depressed patient energy
Regular suitable treatment is enough received, anxiety disorder is so far without special effective anxiolytic drugs.
Drug therapy is undoubtedly the effective ways of anxiety disorder, treating depression, and the anxiolytic drugs of clinical use is with calmness
Based on somnifacient and antidepressants, special anxiolytic drugs is had no.Antidepressants experienced the development course of three generations altogether；First
On behalf of tricyclic antidepressant, drug is represented as imipramine, amitriptyline, doxepin etc.；Second generation antidepressants are and monoamine
Oxidase inhibitor, representing drug has Moclobemide；Third generation antidepressants are that 5-HT reuptaking inhibitor (SSRIs) (is represented
Drug is Prozac, Paxil, Sertraline etc.) and norepinephrine-(represent drug has rice to serotonin energy antidepressant
Flat, Venlafaxine of nitrogen etc.).World's antidepressants product is broadly divided into following six class：Tricyclic antidepressant (tricyclic
Antidepressants, TCA), monoamine oxidase inhibitors (monoamine oxidase inhibitor, MAOI), selection
Property serotonin (5-HT) reuptaking inhibitor (selective serotonin reuptake inhibitors, SSRIs),
Norepinephrine and specific serotonin energy antidepressant (noradrenergic and specific
Serotonergic antidepressant, NaSSA) and serotonin and norepinephrine reuptake inhibitors
(serotonin and norepinephrine reuptake inhibitors, SNRI) and other classes.First generation antidepression
Medicine has been rarely employed now because its target spot specificity is not strong and has larger toxicity.Present clinic be using a line antidepression
Medicine is the second generation and the third generation.But there is the disadvantages of slow, adaptation population is few that works in these drugs.With the increasing of incidence of depression
Add, more stringent requirements are proposed for the clinical research and development to antidepressant.Development efficacy is more preferable, less adverse effect, rarer medicine
The newly-developed antidepressant of object interaction is necessary,
Home-made occluder is Thymelaeceae (Thymelaeaceae) plant suspension culture of Aquilaria sinensis (Aquilaria sinensis (Lour.)
Gilg.) containing the timber of resin.It is distributed mainly on the torrid zone or subtropical zone, is distributed in Guangdong, Guangxi, Yunnan, sea in China
The ground such as south, Taiwan have the function of that promoting qi circulation and relieving pain, warming middle energizer to arrest vomiting, gas of receiving are relievingd asthma.Agalloch eaglewood is medicinal very extensive, and 2015 editions《In
State's pharmacopeia》In there are 35 prescribed preparations to contain agalloch eaglewood, have more than 160 kinds in China with the Chinese patent drug of agalloch eaglewood prescription compatibility,《TCM Recipe
Agent voluminous dictionary》In have 414 prescriptions containing agalloch eaglewood.Due to artificial destruction, wild resource destroys totally substantially, has been included in
《Convention on International Trade in Endangered Species of Wild Fauna and Flora》Annex two.This research solves the problems, such as agalloch eaglewood resource in seminar, realizes
On the basis of scale industrialization production agalloch eaglewood, it was found that it is with significant antianxiety and antidepressant effect.
Summary of the invention
Mirror with this, it is an object of the invention to propose a kind of antidepressant application of agalloch eaglewood effective part extract antianxiety and
Preparation method.The agalloch eaglewood effective part extract that the present invention obtains has significant antianxiety and antidepressant effect.
The technical proposal of the invention is realized in this way：
Agalloch eaglewood effective part extract has the drug or health food of antianxiety or antidepressant effect applied to preparation.
The preparation method of the agalloch eaglewood effective part extract, includes the following steps：
S1-1, it takes agalloch eaglewood to be added in water or alcohol to impregnate；
S1-2, decoction, filtering；
S1-3, filtered dregs of a decoction addition water or alcohol extracting, filtering, merging filtrate are collected；
S1-4, filtrate decompression is concentrated；
S2-1, the medical fluid after concentration is added to water, heating stirring makes to dissolve, and stands, filters to get filtrate；
S2-2, by gained filtrate after organic solvent degreasing is handled, extracted with organic solvent；
S2-3, the concentrated drying of gained extracting solution are to get active component；Or macroporous absorption is added in obtained extracting solution
It is adsorbed in resin column, flushing resin column is colourless to eluent, and eluting solvent is then added into resin column, collects elution
Liquid is concentrated and dried, and obtains effective part extract.
Further, the preparation method of the agalloch eaglewood effective part extract includes the following steps：
S1-1, agalloch eaglewood is taken to be added to 2~12h of immersion in water or alcohol；
S1-2, decoct several times, 1~3 hour every time, filtering；
S1-3, filtered dregs of a decoction addition water or alcohol extracting are collected several times, filtering, merging filtrate；
S1-4, filtrate decompression being concentrated, is heated to 50~70 DEG C, heat surveys the concentrate that relative density is 1.10~1.30,
Concentrate is cooled to room temperature；
S2-1, by the medical fluid after concentration, by crude drug weight：Water volume ratio is 0.5~3：1 ratio is added to the water, heating
It to 30~50 DEG C, is stirred to dissolve, stands 2~24 hours, filter to get filtrate；
S2-2, by gained filtrate after organic solvent degreasing is handled, extracted with organic solvent；
S2-3, the concentrated drying of gained extracting solution are to get active component；Or macroporous absorption is added in obtained extracting solution
It is adsorbed in resin column, flushing resin column is colourless to eluent, and eluting solvent is then added into resin column, collects elution
Liquid is concentrated and dried, and obtains effective part extract.
Preferably, it in step S1-2, decocts 3 times, the NaCl aqueous solution that mass concentration is 5~10% is added for the first time and carries out
It decocts 60~70 minutes, the NaCl aqueous solution that second of addition mass concentration of the filtered dregs of a decoction is 20~30% carries out decoction 90
~100 minutes, filtered dregs of a decoction third time was added the NaCl aqueous solution that mass concentration is 1~5% and carries out decoction 120~150
Minute.
Preferably, in the step S2-2, the organic solvent for degreasing is petroleum ether, benzene, chloroform, ethyl acetate, ring
Hexane or n-hexane, for extraction organic solvent be acetone, ethyl alcohol, methanol, n-butanol, propyl alcohol, isopropanol, ethyl acetate,
Water, ethanol-water solution or methanol-water solution.
Preferably, in the step S2-3, the eluting solvent is water, methanol, ethyl alcohol, acetone, volume fraction be 50~
The aqueous acetone solution that 95% ethanol water or volume fraction is 50~95%.
The present invention also proposes that one kind has antianxiety, antidepressant medicinal plant extract, effective containing above-mentioned agalloch eaglewood
Extractive part.
The present invention also proposes a kind of antianxiety medicine composition for treating depression containing agalloch eaglewood effective part extract, will be described
Powder, tablet, pill, dispersing agent, capsule, soft capsule, dripping pill, granule, effervescent tablet, tea bag, mouth is made in pharmaceutical composition
Take liquid or health drink.
The present invention also proposes that a kind of drug or health food with antianxiety, antidepressant effect, raw material components include
Agalloch eaglewood volatile oil and above-mentioned agalloch eaglewood effective part extract.
Compared with prior art, beneficial effects of the present invention are：
The present invention proposes a kind of agalloch eaglewood effective part extract, with the antidepressant effect of significant antianxiety, passes through
The agalloch eaglewood effective part extract that the preparation method of agalloch eaglewood effective part extract proposed by the present invention obtains, which has, more preferably to be resisted
Anxiety and antidepressant effect can be used as preparing antianxiety and antidepressant active drug or health care product, simultaneously for further comprehensive
It closes and utilizes medicinal material, drive the expanding economy of south of the Five Ridges medicinal material that there is critically important realistic meaning.
Specific embodiment
For the technical solution in the present invention is clearly and completely described in conjunction with the embodiments, it is clear that inventor says
It is bright, but it is only a part of the embodiment of the present invention that following embodiment is described, instead of all the embodiments.Based on the present invention
In embodiment, every other implementation obtained by those of ordinary skill in the art without making creative efforts
Example, shall fall within the protection scope of the present invention.
The present invention proposes that agalloch eaglewood effective part extract can be applied to the drug that preparation has antianxiety or antidepressant effect
Or health food, and there is significant antianxiety or antidepressant effect.
The preparation method of the agalloch eaglewood effective part extract, includes the following steps：
S1, extraction：
S1-1, agalloch eaglewood is taken, cleans, breaks into pieces with one's fingers, be added to 2~12h of immersion in 10~30 times of water or alcohol；
S1-2,2~4 times, 1~3 hour every time, filtering are decocted；
S1-3, filtered dregs of a decoction addition water or alcohol extracting 1~3 time, filtering, merging filtrate are collected；
S1-4, filtrate decompression being concentrated, is heated to 50~70 DEG C, heat surveys the concentrate that relative density is 1.10~1.30,
Concentrate is cooled to room temperature.
S2, purifying：
S2-1, by the medical fluid after concentration, by crude drug weight：Water volume ratio is 0.5~3：Neutral water is added in 1 ratio, adds
Heat is stirred to dissolve to 30~50 DEG C, is stood 2~24 hours, is filtered to get filtrate；
S2-2, by gained filtrate after organic solvent degreasing is handled, extracted with organic solvent；
S2-3, the concentrated drying of gained extracting solution are to get active component；
Or obtained extracting solution is added in the large pore resin absorption column that has loaded, with distilled water flushing resin column,
It is colourless to eluent, eluting solvent is then added into resin column, collects eluent, is concentrated and dried, obtains active component and mention
Take object.
Wherein, in above-mentioned steps S2-2, the organic solvent for degreasing is petroleum ether, benzene, chloroform, ethyl acetate, hexamethylene
Alkane or n-hexane.
Organic solvent for extraction is acetone, ethyl alcohol, methanol, n-butanol, propyl alcohol, isopropanol, ethyl acetate, water, second
Alcohol-water solution or methanol-water solution.
In above-mentioned steps S2-3, the eluting solvent is water, methanol, ethyl alcohol, acetone, volume fraction are 50~95% second
The aqueous acetone solution that alcohol solution or volume fraction are 50~95%.
Used macroporous absorbent resin is D series, HPD series, HP series, XAD series or AB-8 macroporous absorbent resin.
The present invention also proposes that one kind has antianxiety, antidepressant medicinal plant extract, including of the present invention heavy
Fragrant effective part extract.
The present invention also proposes a kind of antianxiety medicine composition for treating depression containing agalloch eaglewood effective part extract, the medicine
Compositions can be made into powder, tablet, pill, dispersing agent, capsule, soft capsule, dripping pill, granule, effervescent tablet, tea bag, mouth
Take liquid or health drink.
The agalloch eaglewood effective part extract that the present invention is prepared can be applied to the preparation antidepressant any medicine of antianxiety
Product or health food.
Embodiment 1
The present invention provides a kind of preparation method of agalloch eaglewood effective part extract, includes the following steps：
S1, extraction：
S1-1, agalloch eaglewood is taken, cleans, breaks into pieces with one's fingers, be added in 10 times of water and impregnate 8h；
S1-2,3 times, 1~3 hour every time, filtering are decocted；
S1-3, filtered dregs of a decoction addition water is collected extraction 3 times, filtering, merging filtrate；
S1-4, filtrate decompression is concentrated, is heated to 60 DEG C, heat surveys the concentrate that relative density is 1.10~1.30, will be dense
Contracting liquid cooling is to room temperature.
S2, purifying：
S2-1, by the medical fluid after concentration, by crude drug weight：Water volume ratio is 2：Neutral water is added in 1 ratio, is heated to 50
DEG C, it is stirred to dissolve, stands 6 hours, filter to get filtrate；
S2-2, by gained filtrate after petroleum ether degreasing is handled, extracted with ethyl alcohol；
S2-3, obtained extracting solution is added in the D-101 large pore resin absorption column loaded, uses distilled water flushing
Then resin column adds water elution until eluent is colourless into resin column, collect eluent, be concentrated and dried, obtain active component
Extract.
Embodiment 2
The research of agalloch eaglewood effective part extract angst resistance effect provided by the invention
Test material：The agalloch eaglewood effective part extract that embodiment 1 obtains is scattered in the active component of physiological saline acquisition
Low dose group (10mg/kg), active component middle dose group (20mg/kg) active component high dose group (40mg/kg) and diazepam
It is scattered in the diazepam group (2.5mg/kg) of physiological saline acquisition.
Experimental animal：Establish model ICR mouse (18~20g)
Test method：Take 18~20g male ICR mouse 60, be randomly divided into 5 groups, respectively blank group, diazepam group,
Active component low dose group, active component middle dose group and active component high dose group, every group of 12 animals, intraperitoneal injection are given
Isometric physiological saline is injected intraperitoneally in relative medicine, blank group.After administration, with higher education plus maze and spacious field experiment detection mouse
Anxiety situation.
Experimental result：
(1) mouse anxiety situation is detected with higher education plus maze (EPM), every mouse is put into one before the test of labyrinth
In 35cm × 10cm × 5cm plastic casing, it is allowed to be immediately placed at the central platform of EPM after freely probing into 5min, makes its head just
It is the following indexs of start recording after release to one of open arms.Every mouse tests 5min.Observation personnel is in distance test
The activity of animal is observed and recorded at case 1.5m respectively, after test result mouse injects experimental drug, open arms time and open arms number
The open arms time of mouse is obviously increased with obviously difference, active component dosage group compared to the blank group, is had aobvious
The angst resistance effect of work.Experimental result is as shown in table 1：
Table 1
Wherein, * * p<0.01.
(2) spacious field (OFT) is tested, and experimental result is as shown in table 2, and each experimental group walking total distance is improved compared with blank group,
Show that active component dosage group can increase Anxiety Model mouse interest-degree under novel environment.
Table 2
Embodiment 3
The research of agalloch eaglewood effective part extract antidepressant effect provided by the invention
Test material：The agalloch eaglewood effective part extract that embodiment 1 obtains is scattered in the active component of physiological saline acquisition
Low dose group (10mg/kg), active component middle dose group (20mg/kg) active component high dose group (40mg/kg) and Prozac
It is scattered in the Prozac group (10mg/kg) of physiological saline acquisition
Experimental animal：Establish model ICR mouse (18~20g)
Test method：Take 18~20g male ICR mouse 60, be randomly divided into 5 groups, respectively blank group, Prozac group,
Active component low dose group, active component middle dose group and active component high dose group, every group of 12 animals, intraperitoneal injection are given
Isometric physiological saline is injected intraperitoneally in relative medicine, blank group.After administration, mouse depression feelings are detected with outstanding tail and forced swimming
Condition.
Experimental result：
(1) tail-suspention test (FST) the results are shown in Table 3, and as can be seen from the results, each experimental group hangs tail motionless total time compared with blank
Group shortens, and active component dosage group can be obviously shortened the depression model mouse tail suspension dead time, this shows active component dosage group
There is significant treatment and abirritation to depression.
Table 3
(2) swimming test (FST), experimental result is as shown in table 4, and each experimental group, which is swum, to contract compared with blank group motionless total time
Short, active component dosage group can be obviously shortened depression model mouse non-swimming time, this shows active component dosage group to suppression
It is strongly fragrant that there is significant treatment and abirritation.
Table 4
Embodiment 4
The present invention provides a kind of preparation method of agalloch eaglewood effective part extract, includes the following steps：
S1, extraction：
S1-1, agalloch eaglewood is taken, cleans, breaks into pieces with one's fingers, be added in 30 times of alcohol and impregnate 2h；
S1-2,3 times, 1~3 hour every time, filtering are decocted；
S1-3, filtered the dregs of a decoction addition alcohol extracting 3 times are collected, filtering, merging filtrate；
S1-4, filtrate decompression is concentrated, is heated to 70 DEG C, heat surveys the concentrate that relative density is 1.10~1.30, will be dense
Contracting liquid cooling is to room temperature.
S2, purifying：
S2-1, by the medical fluid after concentration, by crude drug weight：Water volume ratio is 0.5：Neutral water is added in 1 ratio, is heated to
It 30 DEG C, is stirred to dissolve, stands 2 hours, filter to get filtrate；
S2-2, by gained filtrate after petroleum ether degreasing is handled, extracted with ethyl alcohol；
S2-3, gained extracting solution are concentrated, are spray-dried to get active component.
The agalloch eaglewood effective part extract that the present embodiment obtains carries out the experimental study of embodiment 2 and 3 respectively, equally also table
Significant antianxiety, antidepressant effect are showed.
In addition, the present invention advanced optimizes the processing step of agalloch eaglewood effective part extract preparation method, i.e., preferably, step
It in rapid S1-2, decocts 3 times, the NaCl aqueous solution that mass concentration is 5~10% is added for the first time and carries out decoction 60~70 minutes, mistake
The NaCl aqueous solution that second of addition mass concentration of the dregs of a decoction after filter is 20~30% carries out decoction 90~100 minutes, after filtering
The dregs of a decoction third time NaCl aqueous solution that mass concentration is 1~5% be added carry out decoction 120~150 minutes, it is rear to filter.Research
It was found that the Optimization Steps can significantly improve the antianxiety of agalloch eaglewood effective part extract, antidepressant effect.
Embodiment 5
The present embodiment the difference from embodiment 1 is that, in step S1-2 decoction process, for the first time be added mass concentration be
5% NaCl aqueous solution decoct 60 minutes, and the NaCl that second of addition mass concentration of the filtered dregs of a decoction is 30% is water-soluble
Liquid decoct 90 minutes, and filtered dregs of a decoction third time is added the NaCl aqueous solution that mass concentration is 5% and carries out decocting 120 points
Clock.Remaining step is identical as implementing 1.Agalloch eaglewood effective part extract obtained carries out embodiment 2 and 3 under the same conditions
Experimental study is demonstrated by more preferably antianxiety, antidepressant effect, as a result as shown in table 5 to 8：
Table 5
Table 6
Table 7
Table 8
Embodiment 6
A kind of antianxiety antidepression powder containing agalloch eaglewood effective part extract, is made of following steps：By embodiment 1
The agalloch eaglewood effective part extract of acquisition pulverizes and sieves, and takes 1 parts by weight of fine powder being sieved, and 3.5 parts by weight of starch, lactose are added
6.5 parts by weight are progressively increased by equivalent, and mixing method is uniformly mixed, and powder is made in method divided dose by measure.
Embodiment 7
A kind of antianxiety antidepression hard capsule containing agalloch eaglewood effective part extract, is made of following steps：It will be real
The agalloch eaglewood effective part extract for applying the acquisition of example 1 pulverizes and sieves, and takes 1 parts by weight of medicinal plant fine powder being sieved, and is added dry
1.1 parts by weight of starch are added 1-3% talcum powder and make glidant, filled after mixing with Capsules and ebonite is made as filler
Wafer.
Embodiment 8
A kind of antianxiety antidepression tablet containing agalloch eaglewood effective part extract, is made of following steps：By embodiment 1
The agalloch eaglewood effective part extract of acquisition pulverizes and sieves, and takes 1 parts by weight of medicinal plant fine powder being sieved, and it is fine that hydroxypropyl is added
It ties up plain 1.1 parts by weight and cooks disintegrating agent, 0.4 parts by weight of medicinal dextrin are added and make adhesive, the ethyl alcohol that appropriate 50-95% is added, which is done, to be moistened
Lubrication prescription, wet granulation, drying, whole grain, the rear mix lubricant that 1-3% is added is uniform, tabletted.
Embodiment 9
A kind of antianxiety antidepression dispersible tablet containing agalloch eaglewood effective part extract, is made of following steps：It will implement
1 parts by weight of agalloch eaglewood effective part extract made from example 1 and 4 parts by weight of carrier material are dissolved in jointly in the ethyl alcohol of 50-95%, are used
After spray drying process is dry, sieving, the microcrystalline cellulose that 2.0 parts by weight are added cooks disintegrating agent, and appropriate superfine silica gel powder is added and helps
Agent is flowed, powder is directly compressed into tablet to get dispersible tablet after mixing.
Embodiment 10
A kind of antianxiety antidepression health drink containing agalloch eaglewood effective part extract, is made of following steps：It will be real
1 parts by weight of agalloch eaglewood effective part extract obtained by example 1 and 0.001 parts by weight co-dissolve of sugar-free sweetener are applied in food grade
In water, the beverage that flavoring agent is prepared into various tastes is added, it is filling rear up to health drink.
This research also found that the agalloch eaglewood effective part extract that the present invention obtains, which is added, in agalloch eaglewood volatile oil significantly to mention
High its antianxiety, antidepressant effect, thus the present invention also propose it is a kind of with antianxiety, the drug of antidepressant effect or health care
Food, raw material components include agalloch eaglewood volatile oil and above-mentioned agalloch eaglewood effective part extract.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Within mind and principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.
Claims (9)
1. agalloch eaglewood effective part extract, which is characterized in that applied to preparation have antianxiety or antidepressant effect drug or
Health food.
2. agalloch eaglewood effective part extract according to claim 1, which is characterized in that preparation method includes following step
Suddenly：
S1-1, it takes agalloch eaglewood to be added in water or alcohol to impregnate；
S1-2, decoction, filtering；
S1-3, filtered dregs of a decoction addition water or alcohol extracting, filtering, merging filtrate are collected；
S1-4, filtrate decompression is concentrated；
S2-1, the medical fluid after concentration is added to water, heating stirring makes to dissolve, and stands, filters to get filtrate；
S2-2, by gained filtrate after organic solvent degreasing is handled, extracted with organic solvent；
S2-3, the concentrated drying of gained extracting solution are to get active component；Or macroporous absorbent resin is added in obtained extracting solution
It is adsorbed in column, flushing resin column is colourless to eluent, and eluting solvent is then added into resin column, collects eluent, dense
It contracts drying, obtains effective part extract.
3. agalloch eaglewood effective part extract according to claim 2, which is characterized in that preparation method includes following step
Suddenly：
S1-1, agalloch eaglewood is taken to be added to 2~12h of immersion in water or alcohol；
S1-2, decoct several times, 1~3 hour every time, filtering；
S1-3, filtered dregs of a decoction addition water or alcohol extracting are collected several times, filtering, merging filtrate；
S1-4, filtrate decompression is concentrated, is heated to 50~70 DEG C, heat surveys the concentrate that relative density is 1.10~1.30, will be dense
Contracting liquid cooling is to room temperature；
S2-1, by the medical fluid after concentration, by crude drug weight：Water volume ratio is 0.5~3：1 ratio is added to the water, and is heated to 30
It~50 DEG C, is stirred to dissolve, stands 2~24 hours, filter to get filtrate；
S2-2, by gained filtrate after organic solvent degreasing is handled, extracted with organic solvent；
S2-3, the concentrated drying of gained extracting solution are to get active component；Or macroporous absorbent resin is added in obtained extracting solution
It is adsorbed in column, flushing resin column is colourless to eluent, and eluting solvent is then added into resin column, collects eluent, dense
It contracts drying, obtains effective part extract.
4. agalloch eaglewood effective part extract according to claim 3, which is characterized in that in preparation methods steps S1-2,
It decocts 3 times, the NaCl aqueous solution that mass concentration is 5~10% is added for the first time and carries out decoction 60~70 minutes, filtered medicine
Slag second is added the NaCl aqueous solution that mass concentration is 20~30% and carries out decoction 90~100 minutes, the filtered dregs of a decoction the
The NaCl aqueous solution that mass concentration is 1~5% is added three times and carries out decoction 120~150 minutes.
5. agalloch eaglewood effective part extract according to claim 3, which is characterized in that in preparation methods steps S2-2,
Organic solvent for degreasing is petroleum ether, benzene, chloroform, ethyl acetate, hexamethylene or n-hexane, for the organic molten of extraction
Agent is acetone, ethyl alcohol, methanol, n-butanol, propyl alcohol, isopropanol, ethyl acetate, water, ethanol-water solution or methanol-water solution.
6. agalloch eaglewood effective part extract according to claim 3, which is characterized in that in preparation methods steps S2-3,
The ethanol water or volume fraction that the eluting solvent is water, methanol, ethyl alcohol, acetone, volume fraction are 50~95% are 50
~95% aqueous acetone solution.
7. one kind has antianxiety, antidepressant medicinal plant extract, which is characterized in that any one containing claim 1 to 6
Agalloch eaglewood effective part extract described in.
8. a kind of antianxiety medicine composition for treating depression containing agalloch eaglewood effective part extract, which is characterized in that by the medicine
Compositions are made powder, tablet, pill, dispersing agent, capsule, soft capsule, dripping pill, granule, effervescent tablet, tea bag, take orally
Liquid or health drink.
9. a kind of drug or health food with antianxiety, antidepressant effect, which is characterized in that its raw material components includes agalloch eaglewood
Agalloch eaglewood effective part extract described in volatile oil and claim 1 to 6 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810608872.4A CN108813614B (en) | 2018-06-13 | 2018-06-13 | Application of agilawood effective part extract in anxiety resistance and depression resistance and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810608872.4A CN108813614B (en) | 2018-06-13 | 2018-06-13 | Application of agilawood effective part extract in anxiety resistance and depression resistance and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108813614A true CN108813614A (en) | 2018-11-16 |
| CN108813614B CN108813614B (en) | 2022-02-01 |
Family
ID=64141347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810608872.4A Active CN108813614B (en) | 2018-06-13 | 2018-06-13 | Application of agilawood effective part extract in anxiety resistance and depression resistance and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108813614B (en) |
Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0396638A1 (en) * | 1988-06-14 | 1990-11-14 | Osama L M Omer | A medicinal herb mixture for the treatment of depression. |
| CN1070942A (en) * | 1992-11-03 | 1993-04-14 | 田士英 | Desinfactant detergent |
| CN1076362A (en) * | 1993-03-08 | 1993-09-22 | 王训华 | The preparation method of royal jelly oral products |
| CN1254713A (en) * | 1998-11-19 | 2000-05-31 | 中国医学科学院药物研究所 | Agarofuran derivatives, their preparing process, medicinal composition containing them and their medicinal usage |
| CN1322721A (en) * | 2000-05-12 | 2001-11-21 | 中国医学科学院药物研究所 | New agarofuran derivatives and their prepn. medicine composition and use as medicine |
| US20040161524A1 (en) * | 2001-06-21 | 2004-08-19 | Yasushi Sakai | Process for producing a plant extract containing plant powder |
| CN101011499A (en) * | 2007-02-05 | 2007-08-08 | 中国药科大学 | Linaloe leaf extract, pharmaceutical and health care uses thereof |
| CN101259158A (en) * | 2007-03-05 | 2008-09-10 | 黑龙江省中医研究院 | Chinese medicine pharmaceutical composition for treating coronary heart disease and preparation |
| CN102210790A (en) * | 2011-05-18 | 2011-10-12 | 中国医学科学院药用植物研究所海南分所 | Compound agilawood essential oil for releasing tension headache |
| CN103251890A (en) * | 2013-05-23 | 2013-08-21 | 张博钧 | Plant essential oil composition and anxiolytic effect thereof |
| CN103789094A (en) * | 2014-01-21 | 2014-05-14 | 广州大学 | Method for extracting agilawood essential oil from agilawood chips |
| CN104547285A (en) * | 2014-12-25 | 2015-04-29 | 电白县南药药业有限公司 | Composition containing eaglewood leaves for soothing nerves and promoting sleep |
| WO2015116460A1 (en) * | 2014-01-28 | 2015-08-06 | Virginia Commonwealth University | 2-substituted-5-hydroxy-4h-chromen-4-ones as novel ligands for the serotonin receptor 2b (5-ht2b) |
| CN105560612A (en) * | 2015-12-03 | 2016-05-11 | 北京中医药大学 | Lignum aquilariae resinatum extract, pharmaceutical composition with same and application thereof |
| CN105560664A (en) * | 2016-03-17 | 2016-05-11 | 黄晓其 | Pharmaceutical composition with tranquilizing effect and preparation method and application of pharmaceutical composition |
| CN107397699A (en) * | 2017-09-28 | 2017-11-28 | 深圳市天香赋生物科技有限公司 | A kind of extracting method of Lignum Aquilariae Resinatum extract |
| CN107746749A (en) * | 2017-09-28 | 2018-03-02 | 江永百润福天然植物科技发展有限公司 | A kind of preparation method and Lignum Aquilariae Resinatum extract from agalloch eaglewood residue production Lignum Aquilariae Resinatum extract |
| CN107753660A (en) * | 2017-11-01 | 2018-03-06 | 中国热带农业科学院热带生物技术研究所 | A kind of Lignum Aquilariae Resinatum extract and its application with acetylcholine esterase inhibition activity |
| CN108002997A (en) * | 2017-12-15 | 2018-05-08 | 中国医学科学院药用植物研究所海南分所 | A kind of Lignum Aquilariae Resinatum extract and its application with preventing or arresting vomiting effect |
| CN110101812A (en) * | 2019-06-10 | 2019-08-09 | 中国科学院西北高原生物研究所 | A kind of Tibetan medicine prescription and preparation method thereof with antidepression |
| EP3611170A1 (en) * | 2017-05-19 | 2020-02-19 | Jingluweidai Information Consulting Service (Beijing) Co Ltd | Antianxiety deuterated compounds and medical use thereof |
-
2018
- 2018-06-13 CN CN201810608872.4A patent/CN108813614B/en active Active
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0396638A1 (en) * | 1988-06-14 | 1990-11-14 | Osama L M Omer | A medicinal herb mixture for the treatment of depression. |
| EP0396638B1 (en) * | 1988-06-14 | 1993-03-24 | OMER, Osama L. M., Dr.Dr. | A medicinal herb mixture for the treatment of depression |
| CN1070942A (en) * | 1992-11-03 | 1993-04-14 | 田士英 | Desinfactant detergent |
| CN1076362A (en) * | 1993-03-08 | 1993-09-22 | 王训华 | The preparation method of royal jelly oral products |
| CN1254713A (en) * | 1998-11-19 | 2000-05-31 | 中国医学科学院药物研究所 | Agarofuran derivatives, their preparing process, medicinal composition containing them and their medicinal usage |
| CN1322721A (en) * | 2000-05-12 | 2001-11-21 | 中国医学科学院药物研究所 | New agarofuran derivatives and their prepn. medicine composition and use as medicine |
| US20040161524A1 (en) * | 2001-06-21 | 2004-08-19 | Yasushi Sakai | Process for producing a plant extract containing plant powder |
| CN101011499A (en) * | 2007-02-05 | 2007-08-08 | 中国药科大学 | Linaloe leaf extract, pharmaceutical and health care uses thereof |
| CN101259158A (en) * | 2007-03-05 | 2008-09-10 | 黑龙江省中医研究院 | Chinese medicine pharmaceutical composition for treating coronary heart disease and preparation |
| CN102210790A (en) * | 2011-05-18 | 2011-10-12 | 中国医学科学院药用植物研究所海南分所 | Compound agilawood essential oil for releasing tension headache |
| CN103251890A (en) * | 2013-05-23 | 2013-08-21 | 张博钧 | Plant essential oil composition and anxiolytic effect thereof |
| CN103789094A (en) * | 2014-01-21 | 2014-05-14 | 广州大学 | Method for extracting agilawood essential oil from agilawood chips |
| WO2015116460A1 (en) * | 2014-01-28 | 2015-08-06 | Virginia Commonwealth University | 2-substituted-5-hydroxy-4h-chromen-4-ones as novel ligands for the serotonin receptor 2b (5-ht2b) |
| CN104547285A (en) * | 2014-12-25 | 2015-04-29 | 电白县南药药业有限公司 | Composition containing eaglewood leaves for soothing nerves and promoting sleep |
| CN105560612A (en) * | 2015-12-03 | 2016-05-11 | 北京中医药大学 | Lignum aquilariae resinatum extract, pharmaceutical composition with same and application thereof |
| CN105560664A (en) * | 2016-03-17 | 2016-05-11 | 黄晓其 | Pharmaceutical composition with tranquilizing effect and preparation method and application of pharmaceutical composition |
| EP3611170A1 (en) * | 2017-05-19 | 2020-02-19 | Jingluweidai Information Consulting Service (Beijing) Co Ltd | Antianxiety deuterated compounds and medical use thereof |
| CN107397699A (en) * | 2017-09-28 | 2017-11-28 | 深圳市天香赋生物科技有限公司 | A kind of extracting method of Lignum Aquilariae Resinatum extract |
| CN107746749A (en) * | 2017-09-28 | 2018-03-02 | 江永百润福天然植物科技发展有限公司 | A kind of preparation method and Lignum Aquilariae Resinatum extract from agalloch eaglewood residue production Lignum Aquilariae Resinatum extract |
| CN107753660A (en) * | 2017-11-01 | 2018-03-06 | 中国热带农业科学院热带生物技术研究所 | A kind of Lignum Aquilariae Resinatum extract and its application with acetylcholine esterase inhibition activity |
| CN108002997A (en) * | 2017-12-15 | 2018-05-08 | 中国医学科学院药用植物研究所海南分所 | A kind of Lignum Aquilariae Resinatum extract and its application with preventing or arresting vomiting effect |
| CN110101812A (en) * | 2019-06-10 | 2019-08-09 | 中国科学院西北高原生物研究所 | A kind of Tibetan medicine prescription and preparation method thereof with antidepression |
Non-Patent Citations (8)
| Title |
|---|
| LIN YANG 等: "Antidepressant abietane Diterpenoids from Chinese Eaglewood", 《JOURNAL OF NATURAL PRODUCTS》 * |
| MIRAGHAEE,S.S 等: "Psychbiological assessment of smoke of agarwood (Aquilaria spp.) in male rats", 《JOURNAL OF APPLIED BIOLOGICAL SCIENCES》 * |
| SHUAI WANG 等: "Agarwood Essential oil Ameliorates Restrain Stress-Induced Anxiety and Depression by Inhibiting HPA axis hyperactivity", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
| WANG SHUAI 等: "Chemical Constituents and Pharmacological Acitivity of Agarwood and Aquilaria Plants", 《MOLECULES》 * |
| 侯金良 等: "沉香片剂小鼠口鼻吸入给药抗焦虑和催眠功效实验研究", 《山东中医药大学学报》 * |
| 杨新 等: "地龙抗凝活性物质提取方法研究"", 《江汉大学学报（自然科学版）》 * |
| 王灿红 等: "沉香挥发油成分-靶点预测研究", 《中国药学杂志》 * |
| 霍会霞 等: "中药沉香的药理作用和质量控制研究进展", 《中国医院用药评价与分析》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108813614B (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101559092B (en) | Application of eucommia ulmoides extracts | |
| CN1853682A (en) | Plant based dietary supplement for improving the duration and quality of sleep | |
| CN103127232A (en) | Total extract for mulberry leaf prescription as well as preparation and usage thereof | |
| CN107233442B (en) | Composition capable of improving gout discomfort symptoms and fingerprint spectrum establishment method | |
| CN105477045A (en) | Traditional Chinese medicine composition containing chrysanthemum and wild chrysanthemum volatile oil and preparation method of traditional Chinese medicine composition | |
| CN106581335A (en) | Medicine composition for treating Alzheimer's disease and preparing method and application thereof | |
| CN102014931A (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN106668564B (en) | Natural medicine composition for improving memory function | |
| KR20100106324A (en) | Antimelancholic medicine prepared with jujube camp material | |
| CN102846967A (en) | A pure-component Chinese medicinal preparation for treating headache and its preparation process | |
| CN101214250B (en) | Use of hederagenin and its derivatives in preparing antidepressant product | |
| CN102178721B (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
| CN103705774A (en) | Compound composition with effect of treating depression as well as preparation method and application thereof | |
| CN103372174B (en) | A kind of herbal mixture that is used for the treatment of depression | |
| CN101677989A (en) | A drug composition for treatment and prevention of ischemic stroke and its preparation methods | |
| CN108813614A (en) | Antidepressant application of a kind of agalloch eaglewood effective part extract antianxiety and preparation method thereof | |
| KR20070085519A (en) | An extractive of piper laetispicum c.dc., its process and its uses | |
| CN101396484A (en) | Composite valerian extract capable of tranquilizing and allaying excitement and production method thereof | |
| CN101301330A (en) | Codonopsis pilosula pollen capsules and preparation thereof | |
| CN110123859B (en) | Chrysanthemum leaf extract for preventing and treating liver injury and application thereof | |
| CN104435298B (en) | A kind of medicine composition for treating depression | |
| CN101433645B (en) | Chinese medicine preparation for resisting depression and stress-induced mental disorder, and preparation method thereof | |
| CN100444849C (en) | New use of tribulus terrestris extraction | |
| CN101077407B (en) | Medicine for treating depression caused by simple emotion factor | |
| CN111053819A (en) | Traditional Chinese medicine composition extract and application thereof in preparation of protein expression regulator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |